Edwards Lifesciences Corp. (EW) Tops Q2 EPS by 11c; Boosts Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Edwards Lifesciences (EW) PT Lifted to $100 at Jefferies Amid Strong Q2
July 30, 2014 6:54 AM EDTJefferies analyst Raj Denhoy reiterated a Buy rating and boosted his price target on Edwards Lifesciences (NYSE: EW) to $100.00 (from $94.00) following strong Q2 results and outlook.
Denhoy comments, "EW posted a high-quality 2Q: (1) US Sapien exceeded estimates despite late XT approval and ongoing... More
